|
[Related PubMed/MEDLINE]
Total Number of Papers: 43
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: sPD-L1 |
| Long Form |
: soluble programmed death ligand 1 |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
Clinical implications of APOBEC3A and 3B expression in patients with breast cancer. |
A3A |
| 2 |
2020 |
Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. |
HCC, TACE |
| 3 |
2020 |
High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma. |
NPC |
| 4 |
2020 |
Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: A monocentric cross-sectional study. |
ILD, RA |
| 5 |
2020 |
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. |
anti-PD-1, NSCLC, PFS, sCD40L, sCD44, sPD-1, VEGF-A |
| 6 |
2020 |
Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. |
EPI, HBV, HCs, sPD-1 |
| 7 |
2020 |
Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity. |
ELISA, PD-1, PD-L1, sPD-1, sPD-1 |
| 8 |
2020 |
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. |
OS, PCNSL, PD-1, PD-L1, PFS |
| 9 |
2020 |
The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas. |
CSF, ELISA, HCs |
| 10 |
2019 |
A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma. |
RCC |
| 11 |
2019 |
Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. |
miRNAs, NSCLC, PS |
| 12 |
2019 |
Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. |
DFS, PTC |
| 13 |
2019 |
Long-term Host Immune Response Trajectories Among Hospitalized Patients With Sepsis. |
HR, hs-CRP |
| 14 |
2019 |
Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study. |
ELISA, NPC |
| 15 |
2019 |
Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. |
ELISA, IHC, PTCL |
| 16 |
2019 |
Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. |
PTCL |
| 17 |
2019 |
Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients. |
HCC, OS |
| 18 |
2019 |
The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. |
DFS, HCC, HR, OS, PD-L1, sPD-1, TILs |
| 19 |
2018 |
Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. |
HCC, RT, SBRT |
| 20 |
2018 |
Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis. |
ALCs, CCI, mHLA-DR, RAP |
| 21 |
2018 |
High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma. |
ELISA, HL, PFS |
| 22 |
2018 |
Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. |
CRDM, DM, HC, IQR, ROC, TIF1-gamma |
| 23 |
2018 |
Multiplexed SERS Detection of Soluble Cancer Protein Biomarkers with Gold-Silver Alloy Nanoboxes and Nanoyeast Single-Chain Variable Fragments. |
sEGFR, sPD-1 |
| 24 |
2018 |
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. |
HRs |
| 25 |
2018 |
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer. |
NSCLC, OS, PD-1, TTF |
| 26 |
2018 |
Soluble programmed death-1 ligand 1(sPD-L1) is significantly reduced in the serum of type 1 diabetes patients. |
--- |
| 27 |
2018 |
[Selection of Chemotherapy Regimen on the Basis of Monitoring NLR and Soluble PD-L1 during CRC Chemotherapy]. |
NLR |
| 28 |
2017 |
Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C. |
CHB, CHC, IFN, SMV, SVR, TVR |
| 29 |
2017 |
Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients. |
AR, ARIA, PD-L1 |
| 30 |
2017 |
Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. |
NSCLC, OS, TRT |
| 31 |
2017 |
Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. |
PC, sPD-1 |
| 32 |
2017 |
The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis. |
HRs, OS |
| 33 |
2017 |
[Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer]. |
RAU, sPD-1 |
| 34 |
2016 |
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. |
HCC, OS, PD-L1 |
| 35 |
2016 |
High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. |
ENKTCL, OS, PFS |
| 36 |
2016 |
[Increased serum levels of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients infected with Brucella]. |
CBA, sPD-1, sPD-1 |
| 37 |
2016 |
[Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications]. |
CEA, DC group, EGFR, ELISA, ROC, TKI, TNAB, WT |
| 38 |
2015 |
Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. |
MM, OS, PFS, PR |
| 39 |
2015 |
[Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism]. |
PD-1, PHA |
| 40 |
2015 |
[Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus]. |
OLP, sPD-1 |
| 41 |
2014 |
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. |
DLBCL, OS |
| 42 |
2014 |
[Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications]. |
ADA, AUC, ELISA, MMP-3, MPE, PD-L1, ROC, RT-PCR, TPE |
| 43 |
2012 |
[The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications]. |
--- |
|
A Search Service for Abbreviation / Long Form
